Money moves: How the biotech market is weathering inflationary storms
Kickstarting the Money Moves series, Pharmaceutical Technology looks at what the biotech market holds for the coming year.
Features
Can the FDA keep the momentum going for rare disease drug approvals?
CMO Moves: Regulatory catalysts for therapy manufacturing -January
Provention’s Tzield can delay type 1 diabetes. But will it reach all patients?
Are we entering the era of biologics for COPD?
CRISPR gene therapies: Is 2023 a milestone year in the making?
Magazine: Humira biosimilars set the stage for long-awaited 2023 US launches
2022 in review: Tracking the ups and downs of pharma deals
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
